Blood test using large oncosomes to find aggressive prostate cancer types
Clinical Translation of a Large Oncosome-Based Prostate Cancer Blood Test
This project is developing a blood test that reads cancer-derived particles to spot aggressive forms of metastatic prostate cancer in men.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11175502 on NIH RePORTER |
What this research studies
You would give blood samples so researchers can isolate large oncosomes, which are big cancer-derived particles found in plasma. The team will measure proteins and RNA in those particles using mass spectrometry and sequencing to define molecular signatures linked to treatment response. They will use about 600 clinically annotated samples collected both retrospectively and prospectively across two sites and move the best signatures into a CLIA laboratory for clinical use. The goal is to track tumor phenotype over time and under treatment pressure for both castration-resistant and hormone-sensitive disease.
Who could benefit from this research
Good fit: Ideal candidates are men with metastatic prostate cancer — including those with castration-resistant or hormone-sensitive disease — especially if the cancer is biologically aggressive.
Not a fit: Men with early localized prostate cancer, unrelated medical conditions, or those unable to provide blood samples or visit participating centers are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this could help doctors identify aggressive prostate cancer sooner and guide more personalized treatment or monitoring without repeated invasive biopsies.
How similar studies have performed: Other liquid biopsy approaches like circulating tumor DNA and exosome tests have shown clinical promise, and early pilot data with large oncosome markers are encouraging but still preliminary.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Freeman, Michael R. — Cedars-Sinai Medical Center
- Study coordinator: Freeman, Michael R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.